Overlooked and Underfollowed
Value, special situations, long only

Stereotaxis - Part 2: Undervalued Robotic Medical Play Versus Peers. A Look Back And A Look Ahead - Perhaps Potential M&A Scenarios?

The previous article (click here) on Stereotaxis (NASDAQ:STXS) concentrated on the substantial valuation discount to its robotic peers and why it appears to be too steep. The speed at which that discount closes will be rapid if, as we suspect, the Company's entry into Japan & US approval of Vdrive return Stereotaxis to year-over-year top line growth in 2014.

As we highlighted in the first article, in this second part of our analysis of Stereotaxis we will discuss the five following points:

    Refinancing of the Healthcare Royalty Partners LP loan, which carries a 16% coupon becomes a real prospect, later this year Potential M&A scenarios that could unfold and why it may make sense for another ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details